Amgen reports a Phase 3 win with Sjögren’s drug candidate

🇺🇸 BioPharma Dive (US) —
Amgen reports a Phase 3 win with Sjögren’s drug candidate

AI Summary

Amgen has reported a Phase 3 trial success for dazodalibep, a drug candidate acquired through the acquisition of Horizon Therapeutics. This candidate targets Sjögren’s syndrome, a challenging autoimmune disorder, marking a significant clinical milestone.

Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.

Markets Deals Health Amgen Phase 3 trial dazodalibep Horizon Therapeutics Sjögren’s syndrome autoimmune disorder drug candidate

Read original source →